1. NTRK2 expression in gastrointestinal stromal tumors with a special emphasis on the clinicopathological and prognostic impacts
- Author
-
Keita Sasa, Raku Son, Akiko Oguchi, Karin Ashizawa, Nobuhiko Hasegawa, Daisuke Kubota, Yoshiyuki Suehara, Tatsuya Takagi, Taketo Okubo, Keisuke Akaike, Kiichi Sugimoto, Makoto Takahashi, Kazuhiro Sakamoto, Takashi Hashimoto, Shinji Mine, Tetsu Fukunaga, Muneaki Ishijima, Takuo Hayashi, Takashi Yao, Yasuhiro Murakawa, and Tsuyoshi Saito
- Subjects
Medicine ,Science - Abstract
Abstract Gastrointestinal stromal tumors (GISTs) are typically characterized by activating mutations of the KIT proto-oncogene receptor tyrosine kinase (KIT) or platelet-derived growth factor receptor alpha (PDGFRA). Recently, the neurotrophic tyrosine receptor kinase (NTRK) fusion was reported in a small subset of wild-type GIST. We examined trk IHC and NTRK gene expressions in GIST. Pan-trk immunohistochemistry (IHC) was positive in 25 (all 16 duodenal and 9 out of 16 small intestinal GISTs) of 139 cases, and all pan-trk positive cases showed diffuse and strong expression of c-kit. Interestingly, all of these cases showed only trkB but not trkA/trkC expression. Cap analysis of gene expression (CAGE) analysis identified increased number of genes whose promoters were activated in pan-trk/trkB positive GISTs. Imbalanced expression of NTRK2, which suggests the presence of NTRK2 fusion, was not observed in any of trkB positive GISTs, despite higher mRNA expression. TrkB expression was found in duodenal GISTs and more than half of small intestinal GISTs, and this subset of cases showed poor prognosis. However, there was not clear difference in clinical outcomes according to the trkB expression status in small intestinal GISTs. These findings may provide a possible hypothesis for trkB overexpression contributing to the tumorigenesis and aggressive clinical outcome in GISTs of duodenal origin.
- Published
- 2024
- Full Text
- View/download PDF